Download now: The Downfall of Cable, and the Rise of 5G!

Marijuana's Shocking Statistics

Written by Alex Koyfman
Posted May 23, 2019

Dear Reader,

Cannabis is definitely the hot investment topic of the year... maybe even of the decade.

It's proven to have greater staying power than cryptos or blockchain, not to mention it's infinitely easier to understand.

It's proven to have strong support from both sides of the political isle — one of the very few issues to do so.

And it's proven to be a highly multifaceted commodity, entering the market in sectors ranging from biotech to skin care.

But despite this lightning-fast mainstreaming process, there are still some facts out there that will both impress and surprise you.

According to a 2016 report from Arcview Market Research, the total market for cannabis in the U.S., in all its various forms, stood at an eye-popping $52 billion.

Black Market Still Reigns Supreme

And yet national legal sales of cannabis and cannabis-derived goods were a paltry $6.2 billion.

That means despite being legalized or decriminalized in more than half of the United States, more than 87% of marijuana transactions, in terms of dollar value, remain illegal.

This number is especially telling considering that between 2001 and 2010, there were more than 8 million marijuana arrests in the U.S., costing the federal, state, and local governments in excess of $3.6 billion. 

Seems like a waste, right? You don't know the half of it.

Back in 2016, Pueblo County, Colorado, a jurisdiction with barely 200,000 residents, managed to rake in an astounding $35 million in revenue and other monetary benefits.

Add to this the fact that medical research into the properties of cannabis and CBD has found highly promising potential in fields such as dementia, epilepsy, and cancer treatment, and it becomes clear that this natural product will be gaining in significance and utility for decades to come.

The Pretenders Are Out There

However, for investors, the question of how to benefit from this industrial and scientific renaissance remains largely unanswered.

Mainstream marijuana stocks have either experienced substantial corrections in recent months or continue to trade at prices that even the most bullish analysts find perplexing.

And as the legal landscape remains uncertain, especially on the federal level, the future sits hidden behind a dense fog consisting of impossible to predict variables.

I was equally bewildered for a long time as well.

Until I found a company that might just have the answer to all these uncertainties.

It operates in multiple American states but also internationally, making it less dependent on any one legislative body — even if that legislative body is the U.S. Congress itself.

It develops and markets cannabis for a variety of uses, from medical to recreational, and products ranging from raw flower to soft drinks and topical oils.

It does business not just by developing its own products, but also by leasing land to other companies operating under their own brands — thereby insulating itself against the ebbs and flows of fortune that all newcomers must face to make it past the startup stage.

The World's Biggest Restaurant Chain Pioneered This Model

To my friends and members of my inner circle, I've started calling this company the “McDonald's of Marijuana” thanks to its incredible versatility.

But here's the best part of all: The company trades for under $0.50.

It's still tiny, despite the large-scale diversification it's already been able to achieve.

And that makes it undervalued.

I can't emphasize enough how explosive this story is right now.

So instead of telling you more about it, let me show you.

To access my video presentation, available to you instantly at no charge, click here.

Fortune favors the bold,

alex koyfman Signature

Alex Koyfman

follow basic@AlexKoyfman on Twitter

Coming to us from an already impressive career as an independent trader and private investor, Alex's specialty is in the often misunderstood but highly profitable development-stage microcap sector. Focusing on young, aggressive, innovative biotech and technology firms from the U.S. and Canada, Alex has built a track record most Wall Street hedge funders would envy. Alex contributes his thoughts and insights regularly to Wealth Daily. To learn more about Alex, click here.

Comments

Buffett's Envy: 50% Annual Returns, Guaranteed